A first-in-human phase 1 study of oral LOXO-338, a selective BCL2 inhibitor, in patients with advanced hematologic malignancies (trial in progress) Meeting Abstract
| Authors: | Kumar, S.; Kapoor, P.; Alencar, A.; Murthy, G. S. G.; Hoffmann, M.; Pagel, J.; Patel, V.; Pauff, J.; Zinzani, P. L.; Le Gouill, S.; Mato, A. R.; Jurczak, W.; Roeker, L. E. |
| Abstract Title: | A first-in-human phase 1 study of oral LOXO-338, a selective BCL2 inhibitor, in patients with advanced hematologic malignancies (trial in progress) |
| Meeting Title: | 19th International Myeloma Society Annual Meeting (IMS) |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 22 |
| Issue: | Suppl. |
| Meeting Dates: | 2022 Aug 25-27 |
| Meeting Location: | Los Angeles, CA |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-08-01 |
| Start Page: | S37 |
| End Page: | S38 |
| Language: | English |
| ACCESSION: | WOS:000895909200061 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(22)00333-0 |
| Notes: | Meeting Abstract: P-003 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
